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OPIOID DOSE REDUCTIONS ASSOCIATED WITH REDUCED PAIN 
SENSITIVITY IN ADULTS WITH CHRONIC LOW BACK PAIN 
JOSEPHINE ISSENMAN 
ABSTRACT 
 Background: Chronic low back pain (CLBP) is the leading cause of disability in 
the United States. People suffering from CLBP often have multiple comorbidities 
including depression, anxiety, and substance use disorder (SUD). Although the opioid 
epidemic has intensified the search for new treatment options, both pharmacological and 
other, opioids still remain the most common treatment for chronic pain. Long-term opioid 
therapy (LTOT) has been shown to lead to opioid-induced hyperalgesia (OIH), an 
increased sensitivity to painful stimuli. It remains unclear, however, the extent to which 
reductions in opioid dose impact OIH. 
Methods: This is a longitudinal cohort study whose primary aim is to determine 
how changes in opioid doses are associated with changes in psychosocial and quantitative 
sensory testing (QST) variables. Participants were 24 adults with CLBP being treated 
with LTOT and visits were conducted on a monthly basis for six months. All 24 
participants were included in the analysis of demographic and psychosocial variables 
(disability, anxiety, depression, opioid misuse, pain severity, pain interference, and 
catastrophizing). A subset of 13 participants were included in the analysis of QST 
variables.  
Results: We found that pressure pain thresholds at the thumb and the trapezius, 
and heat pain threshold significantly (p < 0.05) improved between visit 1 and visit 6. We 
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also found that a decrease in morphine equivalent doses (MED) is correlated (coefficient 
> 0.2) with improvements in punctuate probe rating, pain pressure at the thumb, and 
maximum cold ratings. 
Discussion: Our results show that reductions in opioid dose are associated with 
reduced pain sensitivity, even while the psychosocial variables studied (including 
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 Chronic low back pain (CLBP) is an increasingly prevalent and costly disease in 
the United States. It is estimated that 70-85% of adult patients will suffer from back or 
neck pain at some point in their lives, and 11% of adults will suffer from daily pain, 
making it the leading cause of disability.1–3 CLBP is the second most common chronic 
pain condition, after cancer, and is on the rise.4 Notably, one study reported that 
prevalence rates for CLBP climbed from nearly 4% in the early 1990s to over 10% in 
mid-2000s. This increase was paired with an increase of those affected seeking out 
healthcare for pain treatment.5 
Pain conditions are known to increase with age and are most common in older, 
female, and non-Hispanic White patients.1,2,6,7 Untreated, pain will further decrease 
independent functioning and self-efficacy in our aging population.6 Prevalence of back 
pain is known to decrease with increasing educational attainment, disproportionately 
impacting those with lower paying jobs and decreased access to health care.7  
People living with chronic pain are more likely to have comorbid diagnoses 
affecting their gastrointestinal, cardiovascular, or respiratory health. They are also more 
likely to suffer from mental illness, insomnia, and obesity.1,2,8 Depression, anxiety, 
somatic symptom disorders, personality disorders, and substance use disorders have all 
been found to be associated with CLBP, with as many as 46% of chronic pain patients 




As the leading cause of disability and second leading cause of sick leave (after the 
common cold), CLBP places a considerable financial burden on the healthcare system. 
CLBP accounts for 25% of all workplace compensation claims, and 33% of all workplace 
compensation spending, costing roughly 50 billion dollars in 2007 alone.1,10 There are 
upwards of 15 million doctor office visits for CLBP every year, although this is likely an 
underestimation of cost because it does not account for other health professionals such as 
chiropractors, and physical or occupational therapists.2 
Since comorbidities and associated healthcare costs increase with chronicity, it is 
important to understand which pain presentations are most likely to become chronic. It 
has been shown that pain in the lumbar region is 2.86 times more likely to become 
chronic compared to pain in the thoracic region. Additionally, individuals experiencing 
pain for longer than 3 months are much more likely to have a worse outlook in terms of 
recovery time and healthcare costs.2 Further, after two years of unemployment related to 
a pain condition, individuals are unlikely to ever return to work. This is due to increased 
inactivity leading to decreased fitness, outdated vocational skills, and prejudices against 
employees returning from disability leave. CLBP is thus further compounded by 
unemployment which has been shown to be correlated with mental illness and lower life 
expectancy.11 
Despite its cost and chronicity, CLBP does not have a gold standard for care and 
treatment. Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually the first line of 
treatment for all classes of CLBP, despite the heterogeneity of this group. CLBP can be 
nociceptive, related to the activation of nociceptors, or neuropathic, related to injury or 
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disease states. These usually present as two different pain phenotypes, with neuropathic 
pain patients reporting higher pain and disability scores.12 
When pain persists or recurs with NSAID use, physicians turn to other 
pharmacological options, including muscle relaxants and benzodiazepines, used to target 
pain with varying effectiveness.13 For example, tricyclic antidepressants, like 
amitriptyline, have been proven to be quite effective at reducing pain in people with 
neuropathic symptoms.14,15 Serotonin noradrenaline reuptake inhibitors, like venlafaxine, 
are effective at decreasing self-reported pain scores in people with some poly-neuropathy 
conditions, including diabetic neuropathy.16 Anticonvulsants, like pregabalin, have been 
proven effective at relieving both peripheral and central neuropathic pain.15 Then there 
are opioids, the most infamous pharmacological option, which are consistently proven 
effective at providing pain relief in the short term.3 
The opioid epidemic has brought issues related to pain control and medication 
prescribing into the national spotlight, leading experts to consider new ways to treat and 
manage pain. Some studies have looked into combining low-dose opioids with other 
drugs in order to reduce opioid intake. One randomized control trial found that the opioid 
Tramadol and acetaminophen had a synergistic effect and that combination tablets were 
an effective way to manage CLBP. They reported that opioids alone should not be the 
first line of defense against pain and that adjunct therapies and management techniques 
should play a role in treatment.17  
Some non-pharmacological management techniques include mindfulness 
mediation and cognitive behavioral therapy (CBT), both of which have been proven to 
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reduce pain severity and sensitivity.4 These methods are often quite cost-effective and 
convenient for patients since they can be conducted online via telemedicine or on an app 
without requiring patients to leave their homes.  
Other treatment options include physical therapy, massage therapy, yoga, and 
more recently, vagal nerve stimulation (VNS).14 One study found that since the vagus 
nerve has projections into the abdomen and the pelvis, VNS can demonstrate 
antinociceptive effects in these regions. VNS has also demonstrated decreased pain 
sensitivity as measured by QST along with reduced anxiety levels.18 
Despite these alternatives and more, opioids are consistently among the most 
prescribed medications.15,19 Since there are a variety of opioids with varying levels of 
potency, doses are converted to morphine equivalent doses (MED). The most commonly 
prescribed opioids are hydrocodone (1 MED) and oxycodone (1.5 MED). Among 
opioids, oxycodone is the most likely to be abused.20  
The majority, up to 80%, of opioid prescriptions are for acute episodes, including 
post-operative pain.21 The recommended number of tablets given to patients at discharge 
after a surgical procedure is between 0-20, where 1 tablet = 5 mg oxycodone = 7.5 MED. 
The specific amount depends on the procedure, with up to 20 tablets given after ACL 
repair and up to 10 tables given after c-section.22  
Although opioids do provide immediate relief against debilitating pain, this relief 
is not permanent or curative. Opioids are addictive and the root cause of an increasing 
number of hospitalizations and deaths. In the United States, hospitalizations due to 
opioids have increased 64% between 2005 and 2014.23 This sharp uptick is due to an 
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increase in both opioid prescribing and opioids being used recreationally, with 70% of 
fatal drug overdoses attributed to prescriptions.24 
Long-term opioid therapy (LTOT), defined as opioid treatment lasting longer than 
90 days, remains poorly studied.25 One study found that while long-term/high dose 
(defined as greater than 20 MED/day) opioid-users only account for 1.5% of the 
population studied, they accounted for more than half of the morphine equivalents 
dispensed.21  LTOT can lead to adverse effects and opioid tolerance. Some of the adverse 
effects noted include gastrointestinal issues, sleep-disordered breathing, bone fractures, 
endocrine dysregulation, and overdose.26  
The opioid epidemic is intrinsically linked to the concept of opioid tolerance, 
meaning a decreased response to opioids with frequent use. Opioid-tolerant patients 
require an increased dose to achieve the same level of relief.23 This is dangerous as 3 
studies have shown that increasing opioid dose is associated with an increased risk of 
overdose.14 The risk of overdose doubles when increasing dosage from 20 MED per day 
to 50 MED per day.22 Polypharmacy, taking many different types of medication for pain 
control, is also known to increase the risk of overdose.27  
Opioid-use disorder (OUD) is the name coined for a group of misuse behaviors 
including not taking opioids as prescribed, getting opioids from multiple providers, and 
combining opioids with stimulants.28 Individuals with a history of substance abuse are 
most at risk for OUD.29 Various checklists and surveys, including the Addiction 
Behaviors Checklist (ABC), the Prescription Drug Use Questionnaire (PDUQ), and the 
Current Opioid Misuse Measure (COMM), have been created and validated to predict 
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which patients will suffer from OUD.30 Thus, patients with high scores are identified and 
can be seen by their prescribing physician more often and monitored closely (ex. pill 
counting and toxicology screening). 
 Opioids bind to three kinds of opioid-receptors in the central nervous system, mu 
(µ), delta (d), or kappa (k). µ-receptor agonists in particular, like morphine or methadone, 
activate the reward system and can lead to both physical and psychological dependence.31 
Physical dependence on opioids is most often characterized by withdrawal, which can be 
induced by removing the opioid agonist or by introducing an opioid antagonist, like 
naloxone. Withdrawal symptoms include chills, aches, vomiting, and diarrhea. 
Psychological dependence, on the other hand, is characterized by fear of increased pain 
or unavailability of opioids which can manifest as sleep disturbances, anxiety, or 
depression.29 The noradrenergic pathway has been shown to play a role in physical 
dependence, while the dopaminergic pathway has been shown to play a role in 
psychological dependence.31  
A more recent finding further complicating the use of opioid medications for 
chronic pain is that they can often make users more sensitive to pain in the long term, a 
phenomenon termed opioid-induced hyperalgesia (OIH). OIH is a different concept from 
opioid tolerance (the increased quantity of opioids needed to reach the same level of 
relief) because it involves a decrease in pain threshold or increase in pain sensitivity.32,33 
This is most often measured through Quantitative Sensory Testing (QST). Although the 
mechanism for OIH is still unclear, it is thought to be due to the balance between the 
antinociceptive effects of the exogenous opioids and the pronociceptive effects of the 
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endogenous response to pain.34 Exogenous opioids mask or delay the pain response, 
rather than eliminate it. 
Previous research has shown that methadone-maintained patients are less tolerant 
of painful stimuli, including cold pain and electrical stimulation, when compared to 
opioid-naïve patients.35–37 One study comparing patients on opioids, opioid-naïve patients 
newly on opioids, and healthy controls found that the opioid positive group had a lower 
threshold for pain than both the opioid-naïve and healthy participants.38 This suggests 
that patients being treated with LTOT are at greater risk for developing OIH. The same 
study also weaned the patients on opioids, halving their doses every 3 days until clean, 
and found that rapid tapering can induce hyperalgesia.  
Hyperalgesia is an increased or abnormal response to a stimulus that is normally 
perceived as painful (e.g., pain from an injury persists for longer than expected or gets 
worse over time), while allodynia is a painful response to a stimulus that is not normally 
perceived as painful (e.g., experiencing pain from a paintbrush on skin). Both 
hyperalgesia and allodynia are measured during QST and play an important role in 
evaluating a patient’s experience of pain.  
A 2008 study showed that following opioid detoxification, patients on LTOT had 
increased pain sensitivity, such that a greater reduction in opioids was associated with 
decreased pain tolerance.39 Other studies have shown that a short-term infusion of 
remifentanil (an opioid analgesic) increases the skin area affected by hyperalgesia and 
allodynia and increases hyperalgesia and allodynia during the withdrawal period.40,41 
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These studies indicate that OIH is exacerbated during the withdrawal period for both 
long-term and short-term opioid users.  
Another study compared the effects of remifentanil to naloxone, a well-known 
opioid antagonist. Remifentanil showed analgesic effects on administration, followed by 
a maximal increase in pain rating about 30 minutes after infusion. Naloxone showed a 
pain increase similar to what was caused during the withdrawal period after remifentanil. 
However, the lasting hyperalgesia effects were greater with remifentanil than with 
naloxone.42 This is strong evidence that exogenous opioids produce hyperalgesia over 
and above what is expected from endogenous opioids.   
However, many case studies have shown that both hyperalgesia and allodynia can 
disappear in the long term after morphine is replaced with an opioid agonist, like 
sufentanil or methadone, or discontinued completely.32,43,44 This is notable because while 
opioids can induce hyperalgesia and allodynia both during LTOT and immediately after 
detoxification, the slow removal of opioids from a treatment regimen may counteract 
these effects, leading to decreases in OIH. 
In addition to understanding the nuanced relationships between slow opioid 
tapering and reduction in OIH, more research is needed to identify for whom opioid 
tapering is most necessary and effective. As noted above, CLBP patients are a high-risk 
group due to their many medical and psychological comorbidities. Some of the predictors 
known to be correlated with worse pain-related outcomes include having another pain 
condition, suffering from depression or anxiety, or catastrophizing.8  
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Pain catastrophizing is a pattern of emotional and cognitive responses to pain that 
include rumination (“I am always thinking about my pain”), magnification (“This is the 
worst pain I can possibly imagine”), and helplessness (“There is nothing I can do about 
my pain”).45 Catastrophizing has been shown to decrease pain tolerance and is associated 
with increased clinical pain, increased disability, and persisting symptoms.46 However, 
we also know that people with high catastrophizing scores respond less well to various 
treatments.47 As such, more effort needs to be put towards treatment options for high-
catastrophizing CLBP patients. 
Catastrophizing is related to the fear-avoidance model. A model in which negative 
beliefs about pain lead to rumination/magnification/helplessness, which in turn lead to 
disuse and distress reinforcing negative beliefs about pain in the first place.46 Pain-related 
fear has also been shown to predict disability and pain intensity.48 More knowledge about 
a patient’s relationship with their pain can help provide targeted therapies and improve 
pain outcomes.  
People living with CLBP are often seen by many providers and have tried many 
treatments, this leads to frustration and can induce or intensify emotional distress.49 The 
biopsychosocial model suggests that these cognitive and emotional processes contribute 
to each individual’s perception of pain.50 All of this underscores that psychosocial factors 
need to be taken into account when studying people with CLBP, especially those being 







The primary aim of this thesis is to determine how changes in opioid doses are 
associated with changes in pain, disability, and OIH as measured by QST in patients with 
CLBP. A secondary aim is to examine the relationship between changes in opioid dose 
and psychosocial variables that have been identified as predictors of poor treatment 




2.1 Participants and Design 
Participants were 24 adults with chronic low back pain being treated with long-
term opioid therapy. They were recruited by emails sent to previous research participants, 
recruitment letters, web advertising, and bulletin board announcements posted within the 
Mass General Brigham (MGB) community.  
The NIH task force on research standards for CLBP defines CLBP as back pain 
that has persisted for a minimum of 3 months and has caused pain for 50% of days in the 
last 6 months. They stratify CLBP by pain intensity, pain interference with normal 
activities, and functional status.51 This study follows these recommendations for reporting 
on CLBP.  
 
Inclusion and Exclusion Criteria 
To be included in the study, participants were required to 1) be older than 25, 2) 
have CLBP lasting for more than 6 months as their primary pain complaint, 3) have 
typical pain ratings ≥ 4/10 on a visual analogue scale, 4) be treated for CLBP with long-
term opioid therapy, and 5) be able to speak and understand English.52 
Participants were excluded from the study if they 1) showed evidence of delirium, 
dementia, psychosis, or other cognitive impairment preventing completion of study 
procedures, 2) have current (i.e., active) substance use disorder (SUD), 3) have a history 
of myocardial infarction or other serious cardiovascular condition, 4) have current 
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peripheral neuropathy, 5) have a current pregnancy, or intention to become pregnant 
during the study, and 6) have a current intrathecal pump. 
 
Design 
This was a longitudinal cohort study. Visits were conducted on a monthly basis 
for six months. At the first visit, participants came in and informed consent was obtained. 
At each visit, they completed a series of questionnaires, including a medication log, the 
Brief Pain Inventory (BPI), the Hospital Anxiety and Depression Scale (HADS), the Pain 
Catastrophizing Scale (PCS), and the Current Opioid Misuse Measure (COMM).53–56 
Participants then underwent QST testing.  
In addition to these questionnaires, at visit 1 participants completed a detailed 
general demographic information survey. Participants completed the Oswestry Disability 
Inventory (ODI) at visits 1 and 6 only.57 In total, each visit lasted about an hour. 
Participants were compensated up to $500 for having completed all 6 visits. All 




Figure 1. Recruitment of Participants. A total of 13 participants completed all 6 
QST visits and were included in the analysis of QST variables. 24 participants 
were included in the analysis of demographic and psychosocial variables. 
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2.2 QST Measures 
 
Punctuate Probe Ratings and Punctuate Probe Temporal Summation 
A standard set of weighted probes (128mN, 256mN, 512mN) was used to 
measure responses to punctuate mechanical stimuli. First, each probe was applied to the 
middle of the middle finger on the non-dominant hand. The participant was asked to 
provide a pain rating from 0-100 for each of the three probes. The average pain rating for 
all three probes was calculated and used to determine sensitivity to punctuate probe pain. 
Then, using the smallest weighted probe that produced a pain rating of more than 
10, a test of temporal summation was performed. For this test, a series of 10 stimuli were 
applied to the same location on the hand. Participants were asked to provide a pain rating 
from 0-100 at the first, fifth, and tenth stimuli. An average of the differences between 
pain ratings at the tenth stimuli and the first stimuli determined each participant’s value 
for temporal summation. High temporal summation is indicative of greater pain 
sensitivity. 
 
Pressure Pain Threshold (Thumb and Trapezius) 
A pressure algometer (Somedic Senselab, Sweden) was used to measure 
responses to pressure stimulation at two sites, bilaterally. Pain pressure thresholds were 
measured twice on the right and left thumbs and twice on the right and left trapezii. 
Mechanical pressure was applied using a 0.5-cm2 probe covered with 1mm 
polypropylene pressure-transducing material. Pressure was increased at a steady rate of 
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30 kPa/second until the subject indicated that the pressure became painful. An average of 
values for pressure at each site determined each participant’s sensitivity to pressure pain.  
 
Heat Pain Threshold 
A computer-controlled system (Medoc) was used to measure heat pain threshold. 
The probe was placed on the underside of the participant’s dominant forearm. As the 
probe warmed up, the participants were asked to press a button when they could first feel 
the warmth and then when the heat first became painful. An average of two values for 
temperature in degrees Celsius at the point when the heat became painful determined 
each participant’s sensitivity to heat. The Medoc is accurate to a tenth of a degree 
Celsius. 
 
Cuff Pressure Temporal Summation 
Cuff pressure algometry was used to measure responses to deep sustained 
mechanical pressure pain. A standard blood pressure cuff was secured around the belly of 
the dominant gastrocnemius muscle and inflated using a Hokanson rapid cuff inflator. 
The cuff pressure was increased in approximately 20 mmHg intervals and participants 
were regularly asked to indicate their pain ratings. The pressure at a pain rating of 
between 35 and 45 out of 100 was recorded.  
The participant was then allowed to rest before completing the second portion of 
the task. The cuff was then inflated to the pressure indicated above and the participant 
was asked to provide a pain rating initially, and every 30 seconds for 2 minutes, as well 
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as 15 seconds after the cuff was deflated. The difference between pain ratings at two 
minutes and initially determined each participant’s value for cuff pressure temporal 
summation. High temporal summation is indicative of greater pain sensitivity. 
 
Conditioned Pain Modulation 
A pressure algometer was used to measure a baseline response to pressure 
stimulation at the trapezius. The participant was then instructed to place their hand into 
the cold-water bath. A circulating water bath (Neslab RTE17) was maintained at a 
temperature of 5°C. The participant was asked to provide a pain rating in their hand as 
well as a pressure pain in their trapezius at 20 seconds. The conditioned pain modulation 
(CPM) index was calculated between the average of baseline pressures and the average of 
pressures at the trapezius after having a hand submerged for 20 seconds. High CPM 
scores are indicative of more endogenous inhibition and better top-down function of 
inhibitory pain control.58 
 
𝐶𝑃𝑀	𝐼𝑛𝑑𝑒𝑥 = 𝑝𝑎𝑖𝑛	𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒	𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑	𝑑𝑢𝑟𝑖𝑛𝑔	𝑐𝑜𝑙𝑑	𝑡𝑎𝑠𝑘 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒	𝑝𝑎𝑖𝑛	𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒	𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑9 	𝑥	100 
 
Cold Pressor Test 
A circulating water bath (Neslab RTE17) was maintained at a temperature of 5°C. 
The participant was again instructed to place their hand into the cold-water bath and keep 
it submerged for as long as they could tolerate, with a maximum time of 3 minutes. The 
 
17 
tolerance time (between 0 and 180 seconds), and a maximum cold pain rating (between 0 
and 100) were recorded for each participant.  
 
2.3 Measures 
General demographic information and health history were collected for each 
participant at the first visit. Previous research has shown that women are more sensitive 
to pain than men and that Black participants are more sensitive to pain than Caucasian 
participants.59 As such we were interested in the sex and race of subjects, as well as 
ethnicity, marital status, disability status, age, and level of education.  
 
MED 
Medication data was collected at each visit and was self-reported. Discrepancies 
in medication data were checked against the participant’s chart in the EPIC medical 
record software. Morphine equivalent doses (MED) or morphine milligram equivalents 
(MME) were calculated for each opiate that participants were taking.3  
 
Pain 
Pain severity and interference were measured using the Brief Pain Inventory 
(BPI).53 Severity measures pain at its best, worst, on average, and currently. The BPI pain 
severity score is a mean of these 4 items, yielding a value between 0-10. Interference 
measures how much pain has interfered with 7 daily activities (general activity, walking, 
work, mood, enjoyment of life, relations with others, and sleep). BPI pain interference 
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score is the mean of these 7 items, yielding a value between 0-10. This mean can be used 
if at least four of seven items have been completed.  
 
Anxiety and Depression 
Anxiety and depression were measured using the Hospital Anxiety and 
Depression Scale (HADS).54 The HADS consists of 7 self-reported items assessing 
anxiety and 7 items assessing depression. The HADS uses a 4-point rating scale from 0 to 
3 that rates levels of anxiety and depression. The anxiety score was calculated by 
summing all 7 anxiety items and the depression score was calculated by summing all 7 
depression items. Each participant is thus given an anxiety and depression score out of 
21. The HADS has shown validity in a literature review comprising 747 papers.60 
 
Pain Catastrophizing 
Pain catastrophizing was measured using the Pain Catastrophizing Scale (PCS).55 
The PCS consists of 13 self-reported items assessing pain-related catastrophizing. The 
PCS uses a 5-point rating scale from 0 (not at all) to 4 (all the time). The PCS score was 
calculated by summing all 13 items, yielding a score between 0-52. The PCS has shown 








Disability was measured using the Oswestry Disability Index (ODI).57 The ODI 
consists of 10 self-reported items assessing disability. The ODI uses a 6-point rating scale 
from 0 (not at all) to 5 (all the time). The ODI score was calculated by summing all items. 
A score of 0-10 indicates minimal disability, 11-20 indicates moderate disability, 21-30 
indicates severe disability, 31-40 indicates crippling disability and 41-50 indicates that 
the participant is bed-bound. The ODI has shown reliability in a comparison of 5 
questionnaires designed to measure disability.61  
 
Opioid Misuse 
Opioid misuse was measured using the Current Opioid Misuse Measure 
(COMM).56 The COMM consists of 17 self-reported items assessing opioid misuse. The 
COMM uses a 5-point rating scale from 0 to 4. The COMM score was calculated by all 
17 summing items, yielding a score between 0-68. The 17 COMM items have shown 
reliability and validity out of a 40-item questionnaire.  
 
2.4 Data Analysis  
 
Missing Data 
If a participant was missing data from a whole visit, we carried forward the data 
from the previous visit presuming no change.62 The only exception to this was for ODI 
data, which was only taken at visit 1 and visit 6. If a participant was missing ODI data, 
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the mean value from all other participants was imputed. If a participant was missing data 
for a variable across all visits, we calculated the mean value for that variable across 
participants and imputed that in. 
 
Analysis 
Data analysis was performed using the Statistical Package for the Social Sciences 
(SPSS). Change scores were calculated between V1 and V6 by subtracting V1 from V6. 
We used independent samples t-tests to identify demographic differences in changes in 
psychosocial and QST variables. We calculated Cohen’s d for effect size.63 Cohen’s d is a 
measure used to determine the magnitude of difference between groups, it is especially 
useful in small samples when statistical significance is unlikely even when meaningful 
differences are observed. We defined significance as p < 0.05. To determine how changes 
in opioid doses are associated with changes in psychosocial and QST variables, we 
conducted bivariate correlations. Each variable was checked for normality. When the data 
was normally distributed, we used Pearson’s correlation coefficient. When the data was 
not normally distributed, we used Spearman’s correlation coefficient. For correlation 









3.1 Participant Characteristics 
 A total of 24 participants met the eligibility criteria and completed the first visit 
(50% female, 41.7% on disability; Table 1). Participants had an average age of 56 and 
were taking an average of 57.8 daily equivalents of morphine at their first visit. This 
sample was mostly white (83.3%), Non-Hispanic (95.8%), unpartnered (62.5% of 
participants were single or divorced), and educated (75% of participants received more 
education after high school). 
13 participants completed visit 6. The large drop-off in participant follow-up is 
attributed to the COVID-19 pandemic as clinical research was deemed non-essential. The 
remainder of the QST analysis will focus on those 13 participants who have data at visit 1 
and visit 6. However, the demographic and psychosocial variables as measured by 
surveys will focus on all 24 participants as participants completed these remotely despite 
the discontinuation of in-person QST laboratory visits.  
At baseline, this sample had a mean pain severity score of 5.40 (range 2.75 - 7.75) 
and a mean pain interference score of 5.34 (range 2.14 - 8.71). These scores are rated 
from 0-10, meaning that on average the sample was experiencing moderate pain. The 
sample had a mean COMM score of 5.95, meaning they were at low risk for opioid 
misuse (scores above 9 can be indicative of problematic drug-related behaviors).  
The sample had wide variability in terms of anxiety (mean 5.78, range 0-17) and 
depression (mean 6.14, range 1-17), both scored out of 21, and in terms of 
catastrophizing (mean 12.82, range 0-42), scored out of 52. Scores above 8 on the HADS 
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are indicative of depression and anxiety, while scores above 30 on the PCS are indicative 
of clinically relevant catastrophizing.54,55 
 
Table 1. Participant Characteristics.  

















Education High School or below 
More than High School 
6 (25) 
18 (75) 




Demographic characteristics of 24 participants collected at visit 1. 
 
3.2 Psychosocial Factors 
We used independent samples t-tests to identify demographic differences in 
changes in psychosocial variables for all 24 participants (Table 2). There was a sex 
difference in pain interference such that men decreased their scores significantly more 
compared with women (p=0.031). There were no significant sex differences in MED, 
ODI, pain severity, COMM, HADS, or PCS change scores. There was a difference 
between partnered and unpartnered participants in anxiety such that individuals with a 
partner became significantly more anxious compared to those without a partner 
(p=0.047). There were no significant differences between partnered and unpartnered 
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participants in MED, ODI, BPI, COMM, depression, or PCS change scores. There were 
no significant differences between levels of education in MED, ODI, BPI, COMM, 
HADS, or PCS change scores. We did not look at change scores with relation to race or 
ethnicity because the sample was predominately White and Non-Hispanic/Latinx. 
 
Table 2. Psychosocial Variables (N=24). 
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-0.09 0.01 0.928 
Descriptive statistics and results of repeated measures t-tests comparing psychosocial 
variables between visit 1 and visit 6. SD, standard deviation; t, t-score; d, Cohen’s d for 




To determine how changes in opioid doses are associated with changes in 
psychosocial variables, we conducted bivariate correlations. There were no associations 
between changes in morphine equivalents and BPI, COMM, HADS, PCS, or ODI change 
scores (Table 3). 
 
Table 3. Correlations for Psychosocial Variables with Morphine Equivalent Dose 
(N=24). 
Variable Correlation with MED Change p-value 
ODI -0.001 0.997 
Pain Severity -0.084 0.697 
Pain Interference 0.014 0.949 
COMM 0.187 0.381 
Anxiety -0.078 0.715 
Depression -0.123 0.568 
Catastrophizing -0.124 0.565 
Spearman correlations between psychosocial variables and MED change for the entire 
sample, where ** indicates a significant correlation coefficient > 0.20. 
 
 
3.3 Quantitative Sensory Testing (QST) Variables 
We used independent samples t-tests to identify demographic differences in 
changes in QST variables for 13 participants who completed testing at visit 1 and visit 6 
(Table 4). There were no significant sex differences or differences between partnered and 
unpartnered participants in QST change scores. Participants with a greater than high 
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school level of education showed a greater improvement in punctuate probe pain ratings 
compared to those with high school or less (p=0.026). There were no other significant 
differences between levels of education in QST change scores. We did not look at change 
scores with relation to race or ethnicity because the sample was predominately White and 
Non-Hispanic/Latinx. 
Among the subset of participants that completed 6 QST visits (N=13), there was a 
significant change in pressure and heat pain tolerance (Figure 2). On average, participants 
were able to tolerate greater pressure at the thumb (310 kPa at visit 1 to 467 kPa at visit 
6) and at the trapezius (393 kPa at visit 1 to 534 kPa at visit 6). On average, they were 
also able to tolerate greater heat pain (43.05°C at visit 1 to 45.02°C at visit 6). There were 
no other significant changes. Maximum cold pain ratings did not change significantly; 
however, the effect size was 0.74 suggesting that with a larger sample we would reach 
significance (Table 4). 
To determine how changes in opioid doses were associated with changes in QST 
variables, we conducted bivariate correlations. Using the correlation coefficient cut-off of 
0.2, change in MED was meaningfully correlated to change in punctuate probe rating 
(Spearman’s rho=-0.281), thumb pain pressure threshold (Spearman’s rho=-0.237), and 
cold pain ratings (Spearman’s rho=0.741). That is, greater reductions in opioid dose were 
associated with greater reductions in pain ratings and decreased pain sensitivity.  
Change in MED was also meaningfully correlated to change in punctuate probe 
temporal summation (Spearman’s rho=0.305). This indicates an increase in pain 
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sensitivity. There are no significant correlations between changes in morphine 
equivalents and change scores for all other QST variables (Table 5). 
 
Table 4. QST Variables (N=13). 
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-5.04 1.39 <0.001** 








-3.80 0.65 0.003** 






-2.55 0.60 0.026** 

















1.20 0.51 0.252 






-0.67 0.16 0.518 






2.03 0.74 0.066 
Descriptive statistics and results of repeated measures t-tests comparing QST variables 
between visit 1 and visit 6. SD, standard deviation; t, t-score; d, Cohen’s d for effect size; 
p, p-value where ** indicates a significant p-value < 0.05. 
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Table 5. Correlations for QST Variables (N=13). 
 
Variable Correlation with MED Change p-value 
Punctuate Probe Rating -0.281** 0.352 
Punctuate Probe Temporal 
Summation 
0.305** 0.312 
Thumb Pain Pressure 
Threshold 
-0.237** 0.435 
Trapezius Pain Pressure 
Threshold 
0.102 0.741 
Heat Pain Threshold 0.192 0.529 
Cuff Pressure Temporal 
Summation 
0.060 0.845 
Conditioned Pain Modulation 
Index 
-0.153 0.619 
Cold Tolerance Time -0.181 0.554 
Maximum Cold Rating 0.741** 0.004 
Spearman correlations between psychosocial variables and MED change for a sample 




Figure 2. Comparison of QST Means Between Visit 1 and Visit 6. A) Punctate probe 
ratings B) Punctuate probe temporal summation (difference between pain ratings at 2 
time points) C) Thumb pain pressure threshold (measured in kPa) D) Trapezius pain 
pressure threshold (measured in kPa) E) Heat pain threshold (measured in °C) F) Cuff 
temporal summation (difference between pain ratings at 2 time points) G) Conditioned 
pain modulation (cold pressure/baseline pressure x 100) H) Cold tolerance time 
(measured in seconds) I) Maximum cold pain rating. Where * indicates a significant p-













Although participants in this study were not involved in any specific tapering 
program, 10 participants were able to successfully wean their opioid doses, and 11 
participants had their opioid doses remain constant. The trend towards lower opioid doses 
is likely an underestimation because opioid doses were carried through unchanged for 
participants who did not complete the later visits. The 10 participants who successfully 
weaned started at an average dose of 79.17 MED and were able to taper their dose an 
average of 50.57 MED to 28.60 MED. On the other hand, the 3 participants who 
increased their dose over the 6-month period only experienced an average increase of 
14.08 MED. 
The Center for Disease Control (CDC) recommends that physicians exercise 
caution when prescribing greater than 50 morphine milligram equivalents, and do not 
recommend exceeding 90 morphine milligram equivalent per day.3 At baseline, our 
sample was taking an average of 57.8 MED/day, with a visit 1 maximum of 240 
MED/day, greatly exceeding the CDC guidelines. In their 2016 guidelines, the CDC 
notes that the risk for fatal overdose increases greatly at doses exceeding 50 MED/day.3 
At visit 6, our sample was taking an average of 38.5 MED/day, dropping below this 
critical value and decreasing the risk of adverse consequences. 
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At visit 1, the most common opioid prescription was Vicodin (hydrocodone/ 
acetaminophen tablets), followed closely by Percocet (oxycodone/paracetamol tablets) or 
oxycontin (oxycodone tablets). 1 mg of hydrocodone is equivalent to 1 mg of morphine, 
while 1 mg of oxycodone is equivalent to 1.5 mg of morphine. This is consistent with the 
literature on this population, where it’s reported that hydrocodone and oxycodone are the 
most prescribed opioids.20 
On average, participants in this study were able to successfully taper their opioid 
use by 20% taper over 6 months. This is a slow taper consistent with a patient-centered 
approach. In a patient-centered approach, patients are offered education regarding opioids 
and partnered with a prescribing physician with the goal of arriving at their lowest 
comfortable dose. Participants taper at their own pace and can pause or stop the taper at 
will. A study evaluating this approach showed that on average participants were able to 
decrease their MED by 50% at 4 months.64 The CDC’s guidelines for a slow-taper 
recommend tapering until the lowest available dose is reached, increasing the time 
between doses, and finally discontinuing use once opioids are taken less than once per 
day.3  
The patient-centered approach lies in contrast to the forced-taper approach. The 
forced-taper approach is a response to the opioid epidemic and the associated 
hospitalizations and deaths. It is also a reaction to the CDC’s guidelines, which are not 
mandatory, as well physicians’ fear of losing their licenses.65 Forced tapering has the goal 
of quickly decreasing opioid doses for patients, especially those treated with high doses 
for many years. This approach requires patients to adhere to a strict taper schedule 
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enforced by their prescribing physician often without their consent.27 Forced tapers can 
have the unintended consequences of increasing withdrawal symptoms, causing patients 
to seek opioids from non-prescription sources, and even consider or attempt suicide.66 
 
Psychosocial 
Pain severity and interference as measured by the BPI and catastrophizing as 
measured by the PCS remained relatively constant over the 6-month period. This is an 
indication that participants were experiencing the same amount of pain despite being on 
less medication. Although the variability in these measures was quite high, participants, 
on average, were not suffering from depression and anxiety and were moderate 
catastrophizers. Over time, there was a very small increase in anxiety, depression, and 
catastrophizing. 
The COMM has a possible range of 0-68. The highest mean of all 6 visits was 
6.87 at visit 5, indicating that this population is at low risk of misuse. Scores above 9 are 
indicative of drug-related problematic behaviors, and only two participants were 
consistently above this threshold. COMM scores also remained relatively constant for the 
duration of the study, indicating that the risk for misuse did not rise as a result of slowly 
decreasing doses. 
Participants who are married or living with a partner experienced significantly 
greater changes in anxiety as measured by the HADS. Participants with a partner had an 
average anxiety score of 3.44, while participants without a partner had an average anxiety 
score of 7.19 at visit 1. Although those with partners had significant increases in anxiety 
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over the course of the 6 months, they were still less anxious than those without a partner, 
indicating that social support is protective against worse psychosocial outcomes. 
As measured by the ODI, participants trended towards being more disabled over 
time. This should intuitively mean that they are less functional. However, various QST 
measures indicate that is not the case. This, along with the slight increase in anxiety and 
depression, could then indicate psychological dependence on opioids. 
 
QST 
Participants were able to tolerate significantly greater pressure pain induced by 
the pressure algometer at both the thumb and the trapezius at visit 6 compared to 
baseline. They were also able to tolerate significantly higher heat pain induced by the 
Medoc. Although it did not reach significance, participants became less sensitive to 
punctuate probe pain over time, summated less with regards to cuff pressure pain, could 
tolerate the cold water for longer, and rated the cold water as being less painful. 
Achieving significance for two different painful stimuli (pressure and temperature) and 
trending towards increased pain tolerance for the other stimuli listed, further 
demonstrates that participants are becoming less sensitive to pain over time.  
There is limited research on whether repeated testing causes improvement in 
scores due to a practice effect. However, one study of 48 healthy participants found that 
an individual’s QST scores remained constant over time.67 This lends support to our 
conclusion that the improvement is due to the decrease in opioid dose and not due to 
training in the QST tasks. 
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Conversely, participants summated more with regards to punctuate probe pain and 
had lower CPM scores (modulation had less of an effect). Although these did not reach 
significance, they do indicate increased pain sensitivity.  
Additionally, the decrease in punctuate pain rating, increased pressure pain 
threshold at the thumb, and decreased cold pain ratings are correlated with decreased 
MED. This signifies that the improved QST measures, and thus decreased pain 
sensitivity, are associated with the slow taper of opioid doses. Conversely, again, the 
increase in punctuate probe temporal summation is correlated with decreased MED and 
increased pain sensitivity. 
Chronic pain is known to cause changes in the central nervous system which can 
augment pain even in unaffected areas, making pain conditions difficult to treat.59 
Patients with CLBP experience increased pain sensitivity throughout their body, well 
beyond their lower back. This is further supported by our findings since decreasing 
opioids even a small amount leads to a decrease in more centralized pain as measured by 
QST. While our participant’s sensitivity to pain is decreasing, their subjective pain 
ratings, their tendency to misuse opioids, their depression and anxiety scores, and their 
catastrophizing scores remain relatively stable.  
 
4.2 Limitations and Future Studies 
Some limitations of our study include the lack of demographic differences in our 
sample, our small sample size, and our lack of more detailed analysis to prove causation. 
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Firstly, previous studies have shown that the burden of CLBP is not shared 
equally between demographics. Normally differences include females reporting greater 
pain intensity compared to males and Black participants demonstrating great pain 
sensitivity compared to White participants.59 Thus, the lack of racial and ethnic variability 
in our sample is inconsistent with the literature. However, it is consistent with the 
population served by BWH. Unlike Boston Medical Center, an urban safety-net hospital, 
BWH tends to serve a more homogenous population.  
Next, our sample size was very small, with many participants not completing all 
six visits. As we mentioned above, the lack of follow-up is due to the COVID-19 
pandemic causing in-person QST testing to be postponed. These participants will be 
invited to participate in their remaining visits as restrictions lift and be included in future 
analyses. Cohen’s d for effect size was calculated for each t-test to account for this 
limitation. 
Finally, our data is longitudinal, but we didn’t analyze to prove causation. The 
conclusions of this study are purely correlational given the small sample size. Subsequent 
studies should use complex longitudinal data analysis (ex. structural equation modeling) 
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